Hypertension Clinical Trial
Official title:
Optimal Remifentanil Site-effect Concentration for Preventing Severe Cough and Hyperdynamic Response During Tracheal Extubation After Sevoflurane vs. Desflurane. A Randomized Clinical Trial
Pain, cough, hypertension and tachycardia are frequent events during extubation due to a secondary stimulation of mechanoreceptors located in the airway. The mechanical effect of the endotracheal tube activates autonomic reflexes, a situation that could potentially impair the clinical condition of patients. Previous studies have used remifentanil during emergence and extubation showing good results to control this reflex response. However, it is unknown so far, the optimal effect site concentration (Ce) of remifentanil to allow a better control of these events with a low incidence of adverse effects after have received inhaled anesthesia plus remifentanil for anesthetic maintenance. This study will determine the Ce of remifentanil associated with a lower proportion of cough and hyperdynamic circulatory response during extubation for emergency after exposure to sevoflurane or desflurane.
Single-center, randomized, double-blind protocol. The investigators aim to include 368
patients under balanced anesthesia with sevoflurane or desflurane to be randomly allocated
into 6 different remifentanil Ce groups [77 individuals in each of interventional groups
(2.0 vs. 2.5 ng/ml) and 30 in each of the control groups (1.0 ng/ml) administrated by a
target-controlled infusion (TCI) system during emergence and tracheal extubation .
Once informed consent is obtained and inclusion/exclusion criteria are met, subjects will be
randomized before starting of the surgical procedure. This information will remain blinded
to the attendant anesthesiologist and the independent evaluator during the process of
extubation, except for type of inhaled anesthetic for maintenance .
The intervention will start when the anesthesiologist decide to suspend the sevorane or
desflurane dial. At this moment, the fresh flow gas of the anesthesia machine will be
adjusted to 7-8 liters per minute and the infusion of remifentanil will be set up to
establish a Ce of 2.0 ng/ml or 2.5 ng/ml. All patients will be extubated only when all of
these three parameters exist: response to name by eyes opening, response to orders of
breathing and mouth opening.
The evaluation and outcomes measurement will include: Presence and intensity of cough and
changes in heart rate and blood pressure during eyes opening in response to calling by name,
tracheal extubation and 2.5 min after, time to get to be extubated after inhaled anesthetic
discontinuation, episodes of hypoxemia and sedation state during the first 25 minutes after
extubation, requirements of rescue analgesia and postoperative nausea and vomit during this
period.
Close monitoring of patients will take place and data will be collected during the
preoperative, intraoperative and postoperative stages until discharge from the post
anesthesia care unit. Lost to follow and adverse events will be assessed. An interim
committee will evaluate partial results of the study when it reaches 25 and 50% of
recruitment, so the investigators can continue building thereof according to analysis
obtained.
Statistical analysis will be performed by a independent statistician based on "intention to
treat" principle. In addition, excluded data and its reasons for exclusion will be
evaluated. For the descriptive exploratory analysis, continuous variables will be presented
as means (standard deviation) or medians (interquartile ranges). The degree of dispersion,
shape and position as the fulfillment of normality will be analyzed using the t of Student
or Mann-Whitney tests as appropriate. Categorical variables will be presented as proportions
and compared using the chi-square or Fisher 's exact tests as appropriate. Time-varying
measures analysis of variance for repeated measures will be used to make comparisons between
groups.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |